DE69940899D1 - AAV Vektoren zur Herstellung der Medikamente zur konvektion-erhöhten Verabreichung - Google Patents
AAV Vektoren zur Herstellung der Medikamente zur konvektion-erhöhten VerabreichungInfo
- Publication number
- DE69940899D1 DE69940899D1 DE69940899T DE69940899T DE69940899D1 DE 69940899 D1 DE69940899 D1 DE 69940899D1 DE 69940899 T DE69940899 T DE 69940899T DE 69940899 T DE69940899 T DE 69940899T DE 69940899 D1 DE69940899 D1 DE 69940899D1
- Authority
- DE
- Germany
- Prior art keywords
- convection
- production
- aav vectors
- methods
- raav
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5184—Virus capsids or envelopes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y401/00—Carbon-carbon lyases (4.1)
- C12Y401/01—Carboxy-lyases (4.1.1)
- C12Y401/01028—Aromatic-L-amino-acid decarboxylase (4.1.1.28), i.e. tryptophane-decarboxylase
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8694998P | 1998-05-27 | 1998-05-27 | |
US13474899P | 1999-05-18 | 1999-05-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69940899D1 true DE69940899D1 (de) | 2009-06-25 |
Family
ID=26775343
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69940899T Expired - Lifetime DE69940899D1 (de) | 1998-05-27 | 1999-05-26 | AAV Vektoren zur Herstellung der Medikamente zur konvektion-erhöhten Verabreichung |
DE69941100T Expired - Lifetime DE69941100D1 (de) | 1998-05-27 | 1999-05-26 | AAV Vektoren zur Herstellung der Medikamente zur konvektion-erhöhten Verabreichung |
DE69929600T Expired - Lifetime DE69929600T2 (de) | 1998-05-27 | 1999-05-26 | Konvektion-erhöhte verabreichung aadc-kodierende aav vektoren |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69941100T Expired - Lifetime DE69941100D1 (de) | 1998-05-27 | 1999-05-26 | AAV Vektoren zur Herstellung der Medikamente zur konvektion-erhöhten Verabreichung |
DE69929600T Expired - Lifetime DE69929600T2 (de) | 1998-05-27 | 1999-05-26 | Konvektion-erhöhte verabreichung aadc-kodierende aav vektoren |
Country Status (9)
Country | Link |
---|---|
US (7) | US6309634B1 (de) |
EP (1) | EP1080202B1 (de) |
JP (2) | JP2002516295A (de) |
AT (3) | ATE435917T1 (de) |
CA (1) | CA2329259C (de) |
DE (3) | DE69940899D1 (de) |
ES (3) | ES2257051T3 (de) |
PT (1) | PT1080202E (de) |
WO (1) | WO1999061066A2 (de) |
Families Citing this family (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030215422A1 (en) | 1996-09-11 | 2003-11-20 | John A. Chiorini | Aav4 vector and uses thereof |
EP1080202B1 (de) * | 1998-05-27 | 2006-01-25 | Avigen, Inc. | Konvektion-erhöhte verabreichung aadc-kodierende aav vektoren |
ES2313784T3 (es) * | 1998-05-28 | 2009-03-01 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Vector aav5 y usos del mismo. |
US6855314B1 (en) * | 2000-03-22 | 2005-02-15 | The United States Of America As Represented By The Department Of Health And Human Services | AAV5 vector for transducing brain cells and lung cells |
US7672712B2 (en) * | 2000-03-30 | 2010-03-02 | The Regents Of The University Of Michigan | Internal marker device for identification of biological substances |
US7098374B2 (en) | 2001-02-09 | 2006-08-29 | University Of Florida Research Foundation, Inc. | Human disease modeling using somatic gene transfer |
US7588757B2 (en) * | 2001-03-14 | 2009-09-15 | Genzyme Corporation | Methods of treating Parkinson's disease using recombinant adeno-associated virus virions |
US7182944B2 (en) * | 2001-04-25 | 2007-02-27 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of increasing distribution of nucleic acids |
US20050191638A1 (en) * | 2002-02-20 | 2005-09-01 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA) |
US20030050273A1 (en) * | 2001-08-29 | 2003-03-13 | Keiya Ozawa | Compositions and methods for treating neurodegenerative diseases |
EP1469730A4 (de) * | 2001-10-30 | 2006-02-01 | Verfahren und zusammensetzungen zur behandlung der parkinson-krankheit | |
US7419817B2 (en) * | 2002-05-17 | 2008-09-02 | The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. | Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography |
US7090836B2 (en) | 2002-06-21 | 2006-08-15 | Institut Pasteur | Vector for expressing α-L-iduronidase and method of treating MPS I by stereotactic injection into the brain of a mammal |
US20050143330A1 (en) * | 2002-09-30 | 2005-06-30 | Ron Mandel | Method for the treatment of Parkinson's Disease |
US7618948B2 (en) * | 2002-11-26 | 2009-11-17 | Medtronic, Inc. | Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA |
US7829694B2 (en) | 2002-11-26 | 2010-11-09 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
US7605249B2 (en) | 2002-11-26 | 2009-10-20 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
US7994149B2 (en) | 2003-02-03 | 2011-08-09 | Medtronic, Inc. | Method for treatment of Huntington's disease through intracranial delivery of sirna |
US7732591B2 (en) * | 2003-11-25 | 2010-06-08 | Medtronic, Inc. | Compositions, devices and methods for treatment of huntington's disease through intracranial delivery of sirna |
PL378110A1 (pl) * | 2003-02-14 | 2006-03-06 | Biogen Idec Ma Inc. | Kaseta ekspresyjna i wektor do przejściowej albo stabilnej ekspresji egzogennych cząsteczek |
US8946151B2 (en) * | 2003-02-24 | 2015-02-03 | Northern Bristol N.H.S. Trust Frenchay Hospital | Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen |
US7963956B2 (en) | 2003-04-22 | 2011-06-21 | Antisense Pharma Gmbh | Portable equipment for administration of fluids into tissues and tumors by convection enhanced delivery technique |
US8927269B2 (en) | 2003-05-19 | 2015-01-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Avian adenoassociated virus and uses thereof |
US7186699B2 (en) | 2003-06-03 | 2007-03-06 | Cell Genesys, Inc. | Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
RU2005138368A (ru) | 2003-06-10 | 2006-07-27 | ЭнЭсДЖЕНЕ А/С (DK) | Улучшенная секреция нейбластина |
US7261882B2 (en) | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
NZ547185A (en) | 2003-10-20 | 2009-03-31 | Nsgene As | In vivo gene therapy of parkinson's disease |
WO2005056807A2 (en) | 2003-12-04 | 2005-06-23 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health | Bovine adeno-associated viral (baav) vector and uses thereof |
US20050208090A1 (en) * | 2004-03-18 | 2005-09-22 | Medtronic, Inc. | Methods and systems for treatment of neurological diseases of the central nervous system |
CN1950397B (zh) | 2004-03-30 | 2012-05-16 | Ns基因公司 | 生长因子NsG33的治疗用途 |
JP2008503590A (ja) * | 2004-06-21 | 2008-02-07 | メドトロニック・インコーポレーテッド | 組成物を細胞にデリバリーするための医学用システム及び方法 |
US20090136552A1 (en) * | 2004-07-30 | 2009-05-28 | Mette Gronborg | Growth factors nsg28, nsg30, and nsg32 |
US20080188431A1 (en) * | 2004-09-08 | 2008-08-07 | Chiorini John A | Transcytosis of Adeno-Associated Viruses |
PT1807009E (pt) | 2004-10-05 | 2015-02-25 | Univ California | Cânula escalonada |
US20060253068A1 (en) * | 2005-04-20 | 2006-11-09 | Van Bilsen Paul | Use of biocompatible in-situ matrices for delivery of therapeutic cells to the heart |
US8283151B2 (en) * | 2005-04-29 | 2012-10-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes |
US20060257912A1 (en) * | 2005-05-06 | 2006-11-16 | Medtronic, Inc. | Methods and sequences to suppress primate huntington gene expression |
US7902352B2 (en) * | 2005-05-06 | 2011-03-08 | Medtronic, Inc. | Isolated nucleic acid duplex for reducing huntington gene expression |
US8524678B2 (en) | 2005-05-31 | 2013-09-03 | The Regents Of The University Of Colorado, A Body Corporate | Method for delivering genes |
US20080280843A1 (en) * | 2006-05-24 | 2008-11-13 | Van Bilsen Paul | Methods and kits for linking polymorphic sequences to expanded repeat mutations |
US9133517B2 (en) | 2005-06-28 | 2015-09-15 | Medtronics, Inc. | Methods and sequences to preferentially suppress expression of mutated huntingtin |
US9089667B2 (en) * | 2005-08-23 | 2015-07-28 | The Regents Of The University Of California | Reflux resistant cannula and system for chronic delivery of therapeutic agents using convection-enhanced delivery |
US7977314B2 (en) | 2005-12-02 | 2011-07-12 | Amorfix Life Sciences Limited | Methods and compositions to treat and detect misfolded-SOD1 mediated diseases |
US20070132284A1 (en) * | 2005-12-06 | 2007-06-14 | Albert Ekladyous | Headliner mounted center high mount stop lamp (chmsl) |
DE602005023550D1 (de) | 2005-12-14 | 2010-10-21 | Licentia Ltd | Verwendungen eines neurotrophischen Faktors |
JP6105187B2 (ja) * | 2006-04-25 | 2017-03-29 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Cns障害の処置のための成長因子の投与 |
EP2023949A4 (de) * | 2006-04-26 | 2009-08-26 | Univ California | Zusammensetzungen und verfahren für konvektionsverstärkte freisetzung von neurotherapeutika mit hohem molekulargewicht |
US9273356B2 (en) | 2006-05-24 | 2016-03-01 | Medtronic, Inc. | Methods and kits for linking polymorphic sequences to expanded repeat mutations |
CA2654498A1 (en) * | 2006-06-06 | 2007-12-21 | Avigen, Inc. | Substituted pyrazolo[1,5-.alpha.]pyridine compounds and their methods of use |
US20080039415A1 (en) * | 2006-08-11 | 2008-02-14 | Gregory Robert Stewart | Retrograde transport of sirna and therapeutic uses to treat neurologic disorders |
WO2008033285A2 (en) * | 2006-09-15 | 2008-03-20 | The Trustees Of Culumbia University In The City Of New York | Delivery of double-stranded rna into the central nervous system |
US8324367B2 (en) | 2006-11-03 | 2012-12-04 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
US9375440B2 (en) * | 2006-11-03 | 2016-06-28 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
US7988668B2 (en) * | 2006-11-21 | 2011-08-02 | Medtronic, Inc. | Microsyringe for pre-packaged delivery of pharmaceuticals |
US7819842B2 (en) * | 2006-11-21 | 2010-10-26 | Medtronic, Inc. | Chronically implantable guide tube for repeated intermittent delivery of materials or fluids to targeted tissue sites |
US20080171906A1 (en) * | 2007-01-16 | 2008-07-17 | Everaerts Frank J L | Tissue performance via hydrolysis and cross-linking |
US20080181876A1 (en) * | 2007-01-30 | 2008-07-31 | Johnson Kirk W | Methods for treating acute and subchronic pain |
EP1970001B1 (de) * | 2007-03-16 | 2014-07-23 | Brainlab AG | Katheter mit Drucksensorik |
US20090036395A1 (en) * | 2007-04-26 | 2009-02-05 | Davidson Beverly L | Rna interference suppression of neurodegenerative diseases and methods of use thereof |
EP2152346B1 (de) * | 2007-05-17 | 2015-12-02 | Medgenesis Therapeutix Inc. | Konvektionsverstärkter abgabekatheter mit entfernbarem versteifungsglied |
EP2530152B1 (de) * | 2007-05-31 | 2017-12-27 | University of Iowa Research Foundation | Reduktion der Off-Target-RNA-Interferenztoxizität |
US20100284984A1 (en) * | 2007-07-30 | 2010-11-11 | University Of Rochester | Adenosine and its mimetics. modulators, transport inhibitors, and receptor agonists as a therapeutic tool to replace or improve the efficacy of deep brain stimulation |
EP2187898B8 (de) * | 2007-09-12 | 2016-09-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Verwendung viraler vektoren, die das cyp46a1 gen tragen, für die behandlung der alzheimer krankheit |
FI20070808A0 (fi) | 2007-10-25 | 2007-10-25 | Mart Saarma | GDNF:n silmukointivariantit ja niiden käytöt |
FI20080326A0 (fi) | 2008-04-30 | 2008-04-30 | Licentia Oy | Neurotroofinen tekijä MANF ja sen käytöt |
CN102027133A (zh) * | 2008-05-07 | 2011-04-20 | 温瑟瑞克斯有限公司 | 鉴定调节癌细胞中Wnt信号传导的化合物的方法 |
WO2010083842A2 (en) | 2009-01-23 | 2010-07-29 | Nsgene A/S | Expression of neuropeptides in mammalian cells |
BRPI1007155A2 (pt) | 2009-01-29 | 2017-05-30 | Univ Of California San Francisco | métodos para tratar um distúrbio neurológico cortical, e para dispensar um agente terapêutico para o córtex em um primata |
SI2424991T1 (sl) | 2009-05-02 | 2018-11-30 | Genzyme Corporation | Genska terapija za nevrodegenerativne motnje |
US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
MX358980B (es) * | 2009-08-25 | 2018-09-11 | The Regents Of The Univ Of California Star | Colocacion optimizada de canula para suministro de terapeuticos al cerebro. |
NZ600104A (en) | 2009-11-09 | 2013-11-29 | Genepod Therapeutics Ab | Novel viral vector construct for neuron specific optimized continuous DOPA synthesis in vivo |
EP2558154B1 (de) | 2010-04-16 | 2020-06-17 | ClearPoint Neuro, Inc. | Chirurgisches mrt-system mit mrt-kompatiblen chirurgischen kanülen zur übertragung einer substanz in den oder aus dem körper eines patienten |
AU2011307488B2 (en) | 2010-10-01 | 2015-08-20 | Hoba Therapeutics Aps | Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain |
US10130687B2 (en) | 2011-01-05 | 2018-11-20 | Rhode Island Hospital | Compositions and methods for the treatment of orthopedic disease or injury |
US9181544B2 (en) | 2011-02-12 | 2015-11-10 | University Of Iowa Research Foundation | Therapeutic compounds |
US20120220648A1 (en) * | 2011-02-24 | 2012-08-30 | National Taiwan University Hospital | Method of Treating Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency Using Adeno-Associated Virus (AAV)-AADC Vector |
JP6007463B2 (ja) * | 2011-04-18 | 2016-10-12 | 国立研究開発法人国立精神・神経医療研究センター | 薬剤送達粒子及びその製造方法 |
WO2013019830A2 (en) | 2011-08-01 | 2013-02-07 | Alcyone Lifesciences, Inc. | Microfluidic drug delivery devices |
KR102075881B1 (ko) | 2011-09-05 | 2020-02-11 | 호바 세라퓨틱스 에이피에스 | 이질통, 통각과민증, 자발통 및 환상통의 치료 |
WO2013155152A1 (en) | 2012-04-10 | 2013-10-17 | The Regents Of The University Of California | Bis-polymer lipid-peptide conjugates and nanoparticles thereof |
TW201412304A (zh) * | 2012-08-17 | 2014-04-01 | Teva Pharma | 瑞沙吉林之非經腸調配物 |
EP2934627B1 (de) | 2012-12-18 | 2021-04-07 | Alcyone Lifesciences, Inc. | Vorrichtungen und verfahren zur verminderung oder verhinderung von rückstrom in einem abgabesystem |
US9463186B2 (en) | 2013-04-15 | 2016-10-11 | Northwestern University | Treatment for dopaminergic disorders |
CA3209821A1 (en) | 2013-05-15 | 2014-11-20 | Regents Of The University Of Minnesota | Adeno-associated virus mediated gene transfer to the central nervous system |
WO2014191630A2 (en) | 2013-05-28 | 2014-12-04 | Helsingin Yliopisto | Non-human animal model encoding a non-functional manf gene |
CN110215595B (zh) | 2013-06-17 | 2022-04-12 | 亚克安娜治疗学有限公司 | 导管末梢保护系统和立体定向固定装置 |
JP6498670B2 (ja) | 2013-07-31 | 2019-04-10 | アルキオーネ・ライフサイエンシズ・インコーポレイテッドAlcyone Lifesciences, Inc. | 薬剤送達、治療、およびモニタリングのためのシステムおよび方法 |
US9891296B2 (en) | 2013-09-13 | 2018-02-13 | MRI Interventions, Inc. | Intrabody fluid transfer devices, systems and methods |
EP3046586B1 (de) | 2013-09-19 | 2021-07-07 | The Regents of The University of California | Behandlungsverfahren mit bis-polymer-lipidpeptid-konjugaten und nanopartikeln daraus |
KR20160147974A (ko) | 2014-05-02 | 2016-12-23 | 젠자임 코포레이션 | 망막 및 cns 유전자 요법을 위한 aav 벡터 |
RU2711147C2 (ru) | 2014-05-20 | 2020-01-15 | Юниверсити Оф Айова Рисерч Фаундейшн | Терапевтические соединения для лечения болезни хантингтона |
US10758484B2 (en) | 2014-08-25 | 2020-09-01 | Nippon Kayaku Co., Ltd. | CED of SN-38-loaded micelles against brain tumor |
CN107073051B (zh) * | 2014-10-21 | 2021-08-24 | 马萨诸塞大学 | 重组aav变体及其用途 |
CN107106689A (zh) * | 2014-11-05 | 2017-08-29 | 沃雅戈治疗公司 | 用于治疗帕金森病的aadc多核苷酸 |
US11242374B2 (en) | 2015-01-22 | 2022-02-08 | Brown University | Minimally-invasive and activity-dependent control of excitable cells |
US10806396B2 (en) | 2015-01-26 | 2020-10-20 | Alcyone Lifesciences, Inc. | Drug delivery methods with tracer |
HUE057272T2 (hu) * | 2015-02-10 | 2022-04-28 | Genzyme Corp | Vírusrészecskék fokozott bevitele a csíkolt testbe és az agykéregbe |
CN106190949B (zh) * | 2015-05-08 | 2020-04-10 | 上海微创心通医疗科技有限公司 | 一种干态动物源性胶原纤维组织材料及其制备方法和生物假体 |
US20190032079A1 (en) | 2015-08-03 | 2019-01-31 | Myodopa Limited | Systemic synthesis and regulation of l-dopa |
IL258030B (en) | 2015-09-23 | 2022-08-01 | Sangamo Therapeutics Inc | Htt suppressing factors and their uses |
CN108472019A (zh) | 2016-01-04 | 2018-08-31 | 亚克安娜生命科学有限公司 | 用于治疗中风的方法和装置 |
EP3393571B1 (de) | 2016-02-17 | 2024-03-06 | ClearPoint Neuro, Inc. | Chirurgische intrabody-flüssigkeitstransferanordnungen mit verstellbarer freiliegender kanüle zur nadelspitzenlänge, zugehörige systeme und verfahren |
CA3019427A1 (en) | 2016-04-15 | 2017-10-19 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type ii |
WO2017198839A1 (en) | 2016-05-20 | 2017-11-23 | Vihinen Mauno | Destabilising domains for conditionally stabilising a protein |
CN110650673A (zh) | 2016-08-30 | 2020-01-03 | 加利福尼亚大学董事会 | 用于生物医学靶向和递送的方法以及用于实践该方法的装置和系统 |
WO2018071831A1 (en) | 2016-10-13 | 2018-04-19 | University Of Massachusetts | Aav capsid designs |
CA3043635A1 (en) | 2016-12-01 | 2018-06-07 | Sangamo Therapeutics, Inc. | Tau modulators and methods and compositions for delivery thereof |
WO2018191450A2 (en) | 2017-04-14 | 2018-10-18 | National Taiwan University Hospital | Gene therapy for aadc deficiency |
US11179411B2 (en) | 2017-05-18 | 2021-11-23 | Kyoto University | Composition for prevention or treatment of spinocerebellar ataxia type 36 |
JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
WO2019018342A1 (en) | 2017-07-17 | 2019-01-24 | Voyager Therapeutics, Inc. | NETWORK EQUIPMENT TRACK GUIDE SYSTEM |
SG11202002457RA (en) | 2017-09-22 | 2020-04-29 | Univ Pennsylvania | Gene therapy for treating mucopolysaccharidosis type ii |
BR112020013994A2 (pt) | 2018-01-12 | 2020-12-08 | Bristol-Myers Squibb Company | Oligonucleotídeos antissenso que direcionam alfa-sinucleína e seus usos |
EP3781074A1 (de) | 2018-05-09 | 2021-02-24 | ClearPoint Neuro, Inc. | Mrt-kompatible intrakorporale flüssigkeitsübertragungssysteme und zugehörige vorrichtungen und verfahren |
US11253237B2 (en) | 2018-05-09 | 2022-02-22 | Clearpoint Neuro, Inc. | MRI compatible intrabody fluid transfer systems and related devices and methods |
TW202012628A (zh) * | 2018-05-15 | 2020-04-01 | 美商航海家醫療公司 | 用於帕金森氏症治療的組成物及方法 |
US11684750B2 (en) | 2019-10-08 | 2023-06-27 | Clearpoint Neuro, Inc. | Extension tube assembly and related medical fluid transfer systems and methods |
EP4333872A1 (de) | 2021-05-06 | 2024-03-13 | Hoba Therapeutics ApS | Vorbeugung und behandlung von chemotherapie-induzierten neuropathischen schmerzen |
WO2023104960A1 (en) | 2021-12-10 | 2023-06-15 | Hoba Therapeutics Aps | Treatment of nociceptive pain |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US4916151A (en) * | 1985-12-05 | 1990-04-10 | Merrell Dow Pharmaceuticals Inc. | Method of treating parkinson's syndrome |
JP2514913B2 (ja) * | 1987-10-19 | 1996-07-10 | 忠三 岸本 | ヒトbcdfを含有する神経系障害治療剤 |
DE3841955A1 (de) * | 1987-12-31 | 1989-07-13 | Asta Pharma Ag | Synergistische kombination von decarboxylasehemmern und l-dopa-pellets |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
US5766948A (en) * | 1993-01-06 | 1998-06-16 | The Regents Of The University Of California | Method for production of neuroblasts |
WO1995005864A1 (en) * | 1993-08-27 | 1995-03-02 | Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | Convection-enhanced drug delivery |
EP0755454B1 (de) | 1994-04-13 | 2008-02-13 | The Rockefeller University | Aav-vermittelte überbringung von dna in zellen des nervensystems |
US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
US6103226A (en) | 1994-08-12 | 2000-08-15 | Arch Development Corporation | Genetically engineered cells that produce produce L. Dopa |
US5599706A (en) * | 1994-09-23 | 1997-02-04 | Stinchcomb; Dan T. | Ribozymes targeted to apo(a) mRNA |
US5667158A (en) | 1995-05-23 | 1997-09-16 | Glaxo Wellcome Inc. | Automated blend reclaim system for pharmaceutical tablet compression machine |
US5677158A (en) | 1995-06-07 | 1997-10-14 | Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
US6004797A (en) | 1995-11-09 | 1999-12-21 | Avigen, Inc. | Adenovirus helper-free recombinant AAV Virion production |
AU3591597A (en) * | 1996-06-28 | 1998-01-21 | Regents Of The University Of California, The | Transformation and genetherapy of cells of the inner ear |
JPH1113A (ja) | 1997-06-12 | 1999-01-06 | Mitsubishi Agricult Mach Co Ltd | 乗用農機 |
EP1080202B1 (de) * | 1998-05-27 | 2006-01-25 | Avigen, Inc. | Konvektion-erhöhte verabreichung aadc-kodierende aav vektoren |
-
1999
- 1999-05-26 EP EP99925906A patent/EP1080202B1/de not_active Expired - Lifetime
- 1999-05-26 AT AT05017045T patent/ATE435917T1/de not_active IP Right Cessation
- 1999-05-26 ES ES99925906T patent/ES2257051T3/es not_active Expired - Lifetime
- 1999-05-26 ES ES05016619T patent/ES2324540T3/es not_active Expired - Lifetime
- 1999-05-26 AT AT05016619T patent/ATE431418T1/de not_active IP Right Cessation
- 1999-05-26 DE DE69940899T patent/DE69940899D1/de not_active Expired - Lifetime
- 1999-05-26 ES ES05017045T patent/ES2326893T3/es not_active Expired - Lifetime
- 1999-05-26 AT AT99925906T patent/ATE316576T1/de not_active IP Right Cessation
- 1999-05-26 WO PCT/US1999/011687 patent/WO1999061066A2/en active IP Right Grant
- 1999-05-26 PT PT99925906T patent/PT1080202E/pt unknown
- 1999-05-26 DE DE69941100T patent/DE69941100D1/de not_active Expired - Lifetime
- 1999-05-26 DE DE69929600T patent/DE69929600T2/de not_active Expired - Lifetime
- 1999-05-26 JP JP2000550525A patent/JP2002516295A/ja active Pending
- 1999-05-26 CA CA002329259A patent/CA2329259C/en not_active Expired - Lifetime
- 1999-06-26 US US09/320,171 patent/US6309634B1/en not_active Expired - Lifetime
-
2001
- 2001-06-21 US US09/887,854 patent/US6953575B2/en not_active Expired - Lifetime
-
2005
- 2005-04-08 US US11/102,521 patent/US7534613B2/en not_active Expired - Fee Related
-
2006
- 2006-05-19 JP JP2006140195A patent/JP2006298926A/ja active Pending
-
2009
- 2009-04-10 US US12/384,935 patent/US8309355B2/en not_active Expired - Fee Related
-
2012
- 2012-10-08 US US13/647,155 patent/US9492415B2/en not_active Expired - Fee Related
-
2016
- 2016-03-25 US US15/081,116 patent/US20160256534A1/en not_active Abandoned
-
2017
- 2017-10-10 US US15/728,570 patent/US20180243249A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20160256534A1 (en) | 2016-09-08 |
US20100104537A1 (en) | 2010-04-29 |
EP1080202B1 (de) | 2006-01-25 |
WO1999061066A2 (en) | 1999-12-02 |
WO1999061066A9 (en) | 2000-03-30 |
DE69929600T2 (de) | 2006-09-07 |
US9492415B2 (en) | 2016-11-15 |
US8309355B2 (en) | 2012-11-13 |
ES2326893T3 (es) | 2009-10-21 |
US20130101510A1 (en) | 2013-04-25 |
PT1080202E (pt) | 2006-05-31 |
US20050180955A1 (en) | 2005-08-18 |
US6953575B2 (en) | 2005-10-11 |
US7534613B2 (en) | 2009-05-19 |
ES2257051T3 (es) | 2006-07-16 |
ES2324540T3 (es) | 2009-08-10 |
US20180243249A1 (en) | 2018-08-30 |
CA2329259A1 (en) | 1999-12-02 |
EP1080202A2 (de) | 2001-03-07 |
US6309634B1 (en) | 2001-10-30 |
DE69929600D1 (de) | 2006-04-13 |
ATE435917T1 (de) | 2009-07-15 |
WO1999061066A3 (en) | 2000-05-04 |
DE69941100D1 (de) | 2009-08-20 |
JP2006298926A (ja) | 2006-11-02 |
ATE316576T1 (de) | 2006-02-15 |
CA2329259C (en) | 2003-08-05 |
US20020141980A1 (en) | 2002-10-03 |
JP2002516295A (ja) | 2002-06-04 |
ATE431418T1 (de) | 2009-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69941100D1 (de) | AAV Vektoren zur Herstellung der Medikamente zur konvektion-erhöhten Verabreichung | |
ATE465267T1 (de) | Rekombinante aav zur herstellung eines medikaments für die gentherapie von muskelzellen | |
DK0764213T3 (da) | Vektorer der koder for rekombinante AAV-genomer | |
JP2021534809A (ja) | Aavカプシドの向性の再指向化 | |
Gouel et al. | Past and future of neurotrophic growth factors therapies in ALS: from single neurotrophic growth factor to stem cells and human platelet lysates | |
DE60315009D1 (de) | Zusammensetzungen zur verabreichung von enzymen involviert im aminosäuremetabolismus durch verwendung rekombinanter adeno-assoziierter virus vironen (raav vironen), und methode und verwendung zur behandlung von aminosäuremetabolischen störungen unter verwendung solcher raav vironen | |
Zheng et al. | Lentiviral vectors and adeno‐associated virus vectors: useful tools for gene transfer in pain research | |
RU2020137429A (ru) | Лечение пигментного ретинита | |
FI962990A0 (fi) | Menetelmä rekombinanttisten adenovirukseen assosioituvien virusten (AAV:iden) valmistamiseksi ja sen käyttöjä | |
RU2018115760A (ru) | Генетическая конструкция | |
WO2000046246A8 (en) | Alpha-2-macroglobulin therapies and drug screening methods for alzheimer's disease | |
ES2062993T3 (es) | Factor de crecimiento humano i semejante a la preproinsulina. | |
FR2717824B1 (fr) | Virus recombinants, préparation et utilisation en thérapie génique. | |
MX2022002961A (es) | Metodos para tratar enfermedades neovasculares oculares usando variantes de aav2 que codifican para aflibercept. | |
MX2021010134A (es) | Virus adenoasociado recombinante para el tratamiento de la neurodegeneracion de inicio en adultos asociada a grn. | |
CN113631225A (zh) | 用于生产aav颗粒的方法和系统 | |
JP2020533968A (ja) | 組換えアデノ随伴ベクター | |
DE60129069D1 (de) | Hepatitis B Virus Vektoren für Gentherapie | |
WO2015148454A1 (en) | Optimized and modified factor viii genes for gene therapy | |
HUP0101355A2 (hu) | Fehérjetermelésre és célba juttatására szolgáló genomi szekvenciák | |
MX2022002960A (es) | Metodos para tratar enfermedades neovasculares oculares usando variantes de aav2 que codifican para aflibercept. | |
UY38881A (es) | Métodos de tratamiento de enfermedades neovasculares oculares utilizando variantes de aav2 que codifican aflibercept | |
PL1664315T3 (pl) | Wektory aav do terapii genowej in vivo reumatoidalnego zapalenia stawów | |
WO2001090189A3 (en) | G-protein coupled receptor org3. | |
Bowles et al. | 1064. Haute Couture Vectors: Solving Clinical Problems with Custom Designed AAV Vectors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |